Nanox Expands AZmed AI in Radiology Workflows
USARAD, a Nanox subsidiary, is extending its collaboration with European MedTech firm AZmed to bring X-ray AI into its radiology platform.
Updated on Nov. 9, 2026 in Healthcare

Nanox subsidiary USARAD Holdings has expanded its collaboration with AZmed to integrate AZmed's X-ray AI suite into USARAD's radiology workflows through Nanox Marketplace. AZmed's AI will route studies automatically and transmit DICOM data to facilities connected through OnePacs, USARAD's cloud PACS platform.
Why it matters
The expansion is intended to help radiologists prioritize and read studies more efficiently, with AI results reaching them inside the systems they already use. USARAD's CEO said the company valued the results of its work with AZmed.
AZmed's Rayvolve suite holds eight FDA clearances across musculoskeletal and chest X-rays, validated in a Radiography journal study of 258,373 X-rays from 100 medical centers in 26 countries. The source does not report measured productivity or accuracy gains from the USARAD integration itself.
The players
Nanox
Nanox is an Israeli medical imaging company headquartered in Petach Tikva that develops digital X-ray systems and operates a software marketplace for radiology AI tools.
AZmed
AZmed is a European MedTech company founded in 2018 that develops FDA-cleared AI software for reading medical images, particularly X-rays.
USARAD
USARAD is a radiologist network and subsidiary of Nanox that operates a cloud PACS platform, OnePacs, used to manage and read medical imaging studies.
The details
AZmed's AI will be delivered through Nanox Marketplace with automated study routing and DICOM transmission to facilities on OnePacs, so results reach radiologists without leaving their existing system. USARAD has worked with AZmed since 2023 and began using AZchest for chest X-rays in 2026, and the suite will be further integrated under the new agreement.
Timeline
2023: USARAD begins working with AZmed.
2026: USARAD extends AZmed use to AZchest for chest X-rays.
November 9, 2026: The expanded collaboration is announced.
RSNA 2026: Nanox and AZmed hold scheduled booth meetings.
Market Landscape
The deal extends FDA-cleared radiology AI products into a distribution marketplace rather than a new clinical pathway, a model that bundles third-party AI into established imaging platforms. It positions Nanox's marketplace as a channel for vendors like AZmed competing to become default AI layers in reading workflows.
Radiologists using connected facilities could see AI findings appear within their existing reading system instead of a separate tool, which may change how they prioritize studies. Patients are unlikely to notice a direct change, since the source reports no new pricing or access terms for the integration.
The takeaway
Radiology AI is increasingly delivered through shared marketplaces and existing imaging platforms rather than standalone tools. Teams evaluating such software should weigh how well it fits their current systems and how its clinical claims are supported.
What happens next
Nanox and AZmed are scheduled to hold booth meetings at RSNA 2026.
Further reading
For broader context on how AI is reshaping clinical care, see the Healthcare section.



